COMMUNIQUÉS West-GlobeNewswire

-
Radius Health to Present at Cowen 39th Annual Healthcare Conference
11/03/2019 -
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019
11/03/2019 -
Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results
11/03/2019 -
ShockWave Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/03/2019 -
Résultats 2018 du HOOPP : tenir la promesse de pension offerte à nos membres
11/03/2019 -
ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
11/03/2019 -
Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
11/03/2019 -
MRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint® Cases
11/03/2019 -
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/03/2019 -
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
11/03/2019 -
Wright Medical Group N.V. Announces Termination of Contingent Value Rights Agreement
11/03/2019 -
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
11/03/2019 -
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
11/03/2019 -
ChromaDex to Present at the 31st Annual ROTH Conference
11/03/2019 -
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
11/03/2019 -
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Financial Results Conference Call and Webcast on March 13, 2019
11/03/2019 -
Bavarian Nordic Announces FDA Delay in the Review of the Biologics License Application for MVA-BN Smallpox Vaccine
11/03/2019 -
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
11/03/2019 -
ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2
11/03/2019
Pages